Anti-inflammatory effects GLP-1 receptor agonists demonstrate anti-inflammatory properties that extend beyond metabolic effects
Silencing P65 or EAAT3 increases ROS levels and reduces GSH synthesis, but these changes alone are insufficient to trigger significant cell death due to the robust ferroptosis-resistance mechanisms in cancer cells, including the xCT-GSH-GPX4 system and other protective pathways
Peptides are being explored for a variety of health issues, including hormone regulation, making them a promising option for menopause treatment
Moreover, the suppression of cardiac inflammation, fibrosis and hypertrophy with GLP-1RA treatment provide a clinically favorable impact on cardiac dysfunction
Encouraged by these results, Novo Nordisk launched the much larger SOUL trial the following year
We are committed to keeping the public informed and will continue to follow the latest clinical trial data, FDA guidance, and regulatory updates surrounding retatrutide and other emerging metabolic therapies